Pharmacokinetic parameter prediction from drug structure using artificial neural networks.

Simple methods for determining the human pharmacokinetics of known and unknown drug-like compounds is a much sought-after goal in the pharmaceutical industry. The current study made use of artificial neural networks (ANNs) for the prediction of clearances, fraction bound to plasma proteins, and volume of distribution of a series of structurally diverse compounds. A number of theoretical descriptors were generated from the drug structures and both automated and manual pruning were used to derive optimal subsets of descriptors for quantitative structure-pharmacokinetic relationship models. Models were trained on one set of compounds and validated with another. Absolute predicted ability was evaluated using a further independent test set of compounds. Correlations for test compounds ranged from 0.855 to 0.992. Predicted values agreed closely with experimental values for total clearance, renal clearance, and volume of distribution, while predictions for protein binding were encouraging. The combination of descriptor generation, ANNs, and the speed and success of this technique compared with conventional methods shows strong potential for use in pharmaceutical product development.

[1]  P. Hinderling,et al.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  H. Black,et al.  A comprehensive review of the clinical pharmacology and pharmacokinetics of cefaclor. , 1988, Clinical Therapeutics.

[3]  T. Ghafourian,et al.  The effect of structural QSAR parameters on skin penetration. , 2001, International journal of pharmaceutics.

[4]  T. Bergan Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration. , 1977, Chemotherapy.

[5]  Romankiewicz Ja,et al.  Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. , 1983 .

[6]  Rf Rekker,et al.  THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .

[7]  K Krishnan,et al.  Quantitative structure-pharmacokinetic relationship modelling. , 2001, The Science of the total environment.

[8]  J Bourquin,et al.  Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. , 1997, Pharmaceutical development and technology.

[9]  M. Ehrnebo,et al.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  P. Veng‐Pedersen,et al.  Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. , 1994, Journal of pharmaceutical sciences.

[11]  M. Schulz,et al.  The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment , 2004, European Journal of Clinical Pharmacology.

[12]  J. Quion,et al.  Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.

[13]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[14]  D. Nicolau,et al.  Lomefloxacin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[15]  D. Maddalena,et al.  Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks. , 1995, Journal of medicinal chemistry.

[16]  U. Gundert-Remy,et al.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment , 2004, European Journal of Clinical Pharmacology.

[17]  L. Benet,et al.  Pharmacokinetics of natural and synthetic glucocorticoids , 1985 .

[18]  M. Feher,et al.  A simple model for the prediction of blood-brain partitioning. , 2000, International journal of pharmaceutics.

[19]  B. Huitfeldt,et al.  Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. , 1986, British journal of clinical pharmacology.

[20]  D. Breimer,et al.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. , 1991, British journal of clinical pharmacology.

[21]  G. Drusano,et al.  Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate , 1989, Antimicrobial Agents and Chemotherapy.

[22]  S. Schenker,et al.  Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. , 1977, Gastroenterology.

[23]  P. Benfield,et al.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. , 1990, Drugs.

[24]  Didier Villemin,et al.  Neural networks studies : quantitative structure-activity relationship of mutagenic aromatic nitro compounds , 1993 .

[25]  W. Shelver,et al.  Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. , 1995, Journal of pharmaceutical sciences.

[26]  Snezana Agatonovic-Kustrin,et al.  Multiple pharmacokinetic parameter prediction for a series of cephalosporins. , 2003, Journal of pharmaceutical sciences.

[27]  T. Schwinghammer,et al.  Pharmacokinetics of Cephradine Administered Intravenously and Orally to Young and Elderly Subjects , 1990, Journal of clinical pharmacology.

[28]  P. Meredith,et al.  Clinical Pharmacokinetics of Amlodipine , 1992, Clinical Pharmacokinetics.

[29]  R. Moore,et al.  Pharmacokinetics of betamethasone in healthy adults after intravenous administration , 2004, European Journal of Clinical Pharmacology.

[30]  Ian Spence,et al.  Selective descriptor pruning for QSAR/QSPR studies using artificial neural networks , 2003, J. Comput. Chem..

[31]  Jerome J. Schentag,et al.  Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients , 1981, Clinical pharmacology and therapeutics.

[32]  U. Stephan,et al.  Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues , 1989, Clinical pharmacokinetics.

[33]  W. Colburn,et al.  Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain , 1987, Clinical pharmacology and therapeutics.

[34]  Facundo Pérez-Giménez,et al.  QSAR Analysis of Hypoglycemic Agents Using the Topological Indices , 2001, J. Chem. Inf. Comput. Sci..

[35]  D. Greenblatt,et al.  Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.

[36]  J. Upward,et al.  Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects , 2004, European Journal of Clinical Pharmacology.

[37]  S. Ōmura,et al.  Inhibition of Sporulation by Cerulenin and Its Reversion by Exogenous Fatty Acids in Saccharomyces cerevisiae , 1976, Antimicrobial Agents and Chemotherapy.

[38]  M. Eichelbaum,et al.  Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose‐dependent clearance, and interaction with amiodarone , 1994, Clinical pharmacology and therapeutics.

[39]  P. Sebel,et al.  The Pharmacokinetics of Sufentanil in Surgical Patients , 1984, Anesthesiology.

[40]  J. Hamilton-miller,et al.  Cefaclor into the millennium. , 1999, Journal of chemotherapy.

[41]  P J Sinko,et al.  Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[42]  F. Sallee,et al.  Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.

[43]  P. Kroboth,et al.  Pharmacokinetics of the Newer Benzodiazepines , 1989, Clinical pharmacokinetics.

[44]  G. Houin,et al.  Clinical Pharmacokinetics of Doxycycline and Minocycline , 1988, Clinical pharmacokinetics.

[45]  K. Hamunen,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children , 1995, Clinical pharmacokinetics.

[46]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[47]  E. Sellers,et al.  Clinical Pharmacokinetics of Non-Opiate Abused Drugs , 1989, Clinical pharmacokinetics.

[48]  P. Welling,et al.  Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. , 1982, Biopharmaceutics & drug disposition.

[49]  A. Favero,et al.  Ondansetron Clinical Pharmacokinetics , 1995, Clinical pharmacokinetics.

[50]  Subhash C. Basak,et al.  Topological Indices: Their Nature and Mutual Relatedness , 2000, J. Chem. Inf. Comput. Sci..

[51]  K. Lauritsen,et al.  Clinical pharmacolinetics of drugs used in the treatment of gastrointestinal diseases. I , 1990 .

[52]  G. Grass,et al.  Effect of diverse datasets on the predictive capability of ADME models in drug discovery , 2001 .

[53]  Y L Loukas,et al.  Quantitative structure-binding relationships (QSBR) and artificial neural networks: improved predictions in drug:cyclodextrin inclusion complexes. , 2001, International journal of pharmaceutics.

[54]  E. Bailey,et al.  Ofloxacin Clinical Pharmacokinetics , 1992, Clinical pharmacokinetics.

[55]  S. Agatonovic-Kustrin,et al.  Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. , 2000, Journal of pharmaceutical and biomedical analysis.

[56]  W. Jusko,et al.  Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[57]  S. So,et al.  Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. , 1992, Journal of medicinal chemistry.

[58]  D. Orth.,et al.  THE ADRENAL CORTEX , 1948 .

[59]  K J Schaper,et al.  Quantitative structure-pharmacokinetic relationships and drug design. , 1981, Pharmacology & therapeutics.

[60]  F. Jamali,et al.  Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.

[61]  D. Greenblatt Clinical Pharmacokinetics of Oxazepam and Lorazepam , 1981, Clinical pharmacokinetics.

[62]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[63]  T. A. Andrea,et al.  Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. , 1991, Journal of medicinal chemistry.

[64]  R. Oberbauer,et al.  Pharmacokinetics of Indomethacin in the Elderly , 1993, Clinical pharmacokinetics.

[65]  C J Timmer,et al.  Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.

[66]  J. Rask-Madsen,et al.  Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.

[67]  J. Flaherty,et al.  Third-generation cephalosporins: a critical evaluation. , 1984, Clinical pharmacy.

[68]  J P Monk,et al.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. , 1987, Drugs.

[69]  Jesús Vicente de Julián-Ortiz,et al.  Topological Approach to Drug Design , 1995, J. Chem. Inf. Comput. Sci..

[70]  P. Dick,et al.  Discrepancies Between Pharmacokinetic Studies of Amitriptyline , 1985, Clinical pharmacokinetics.

[71]  T. Hatanaka Clinical Pharmacokinetics of Pravastatin , 2000, Clinical pharmacokinetics.

[72]  Ramón García-Domenech,et al.  Topological Approach to Analgesia , 1994, J. Chem. Inf. Comput. Sci..

[73]  A. Burm,et al.  Clinical Pharmacokinetics of Epidural and Spinal Anaesthesia , 1989, Clinical pharmacokinetics.

[74]  M. Eichelbaum,et al.  Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem , 1986, Clinical pharmacokinetics.

[75]  D. Spyker,et al.  Pharmacokinetics of Cefaclor and Cephalexin: Dosage Nomograms for Impaired Renal Function , 1978, Antimicrobial Agents and Chemotherapy.

[76]  A. Munafo,et al.  Disposition and irreversible plasma protein binding of tolmetin in humans , 1988, Clinical pharmacology and therapeutics.

[77]  L. Hall,et al.  Molecular Structure Description: The Electrotopological State , 1999 .

[78]  S. Unger Molecular Connectivity in Structure–activity Analysis , 1987 .